Skip to main content

Fresenius is a global healthcare group. We offer system-critical products and services for leading therapies for care of critically and chronically ill patients. With over 300,000 employees around the globe, and annual sales exceeding €40 billion, Fresenius is one of the world’s leading healthcare companies.

The Fresenius Group comprises the Operating Companies Fresenius Kabi and Fresenius Helios and the Investment Companies Fresenius Medical Care and Fresenius Vamed. Each business segment is market leader in a major growth area of healthcare.

  • Fresenius Kabi supplies healthcare products for critically and chronically ill patients
  • Fresenius Helios is Europe’s leading private hospital operator 
  • Fresenius Medical Care offers dialysis products and services 
  • Fresenius Vamed specializes on project business and management of healthcare facilities

Fresenius continuously develops its business areas. With the #FutureFresenius program, the focus will be on three therapy platforms: 

  • (Bio)Pharma including clinical nutrition
  • MedTech
  • Care Provision

With these platforms, Fresenius caters to major trends in healthcare and becomes a more therapy-focused company. The health and quality of life of patients who the company serves with high-quality, affordable products and services is at the core. 

At Fresenius, the patient always comes first. For more than 100 years now we have been working to save lives and improve the quality of life of our critically and chronically ill patients. A clear focus on innovation and efficiency has helped us to make world-class therapies accessible to a steadily increasing number of people. Yet we never get complacent about our successes, and never stop looking for better solutions. This is how Fresenius is contributing to medical progress and better patient care.

Success in our business is the key for investing in high-quality yet affordable healthcare. In this way we are meeting our social responsibility to help patients, while ensuring that Fresenius remains successful over the long term.

Fresenius leads by recognizing important trends and developments early, then working with our partners to help shape healthcare systems. Aging populations and the expansion of healthcare provision in countries worldwide are driving demand for medical products and services, and Fresenius is excellently positioned for continuous and profitable growth in the future.

“Advancing patient care” – we strive to improve continuously and to shape the future of healthcare as an industry-leading, therapy-focused healthcare company. 

Fresenius Image Film

Fresenius Group in figures (IFRS)

€ in millions 2022 2021 2020


40,840 37,520 36,277


4,004 4,252 4,612

EBIT margin 

9.8% 11.3% 12.7%


3,465 3,117 3,300

Net income

1,729 1,867 1,796

Operating cash flow

4,198 5,078 6,549

Employees (December 31)

316,920 316,078 311,269

  • Some figures adjusted for special items

Group Sales by business segment

€ in millions 2022 2021 Growth

Fresenius Kabi

7,850 7,193 4 %

Fresenius Helios

11,716  10,891 7 %

Fresenius Medical Care

19,398 17,619   2 %

Fresenius Vamed

2,359 2,297 2 %


Fresenius SE & Co. KGaA
Else-Kröner-Str. 1
61352 Bad Homburg
T: +49 6172 608-0